0 161

Cited 43 times in

Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy

 Hanna Cho  ;  Jae Yong Choi  ;  Mi Song Hwang  ;  Seung Ha Lee  ;  Young Hoon Ryu  ;  Myung Sik Lee  ;  Chul Hyoung Lyoo 
 Movement Disorders, Vol.32(1) : 134-140, 2017 
Journal Title
 Movement Disorders 
Issue Date
Aged ; Carbolines* ; Cerebellar Nuclei/diagnostic imaging ; Cerebellar Nuclei/metabolism* ; Female ; Globus Pallidus/diagnostic imaging ; Globus Pallidus/metabolism* ; Humans ; Male ; Middle Aged ; Parkinson Disease/diagnostic imaging ; Parkinson Disease/metabolism* ; Positron-Emission Tomography/methods* ; Putamen/diagnostic imaging ; Putamen/metabolism* ; Subthalamic Nucleus/diagnostic imaging ; Subthalamic Nucleus/metabolism* ; Supranuclear Palsy, Progressive/diagnostic imaging ; Supranuclear Palsy, Progressive/metabolism* ; tau Proteins/metabolism*
18F-AV-1451 ; PET ; Parkinson's disease ; Progressive supranuclear palsy ; tau
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological substrate for progressive supranuclear palsy (PSP). 18 F-AV-1451, a radiotracer that binds to the pathological tau protein, may be helpful for in vivo visualization and quantitation of tau pathology in PSP. OBJECTIVES: The objectives of this study were to investigate cortical and subcortical 18 F-AV-1451 binding patterns in patients with PSP. METHODS: We recruited 14 PSP patients and compared their cortical and subcortical binding patterns in 18 F-AV-1451 positron emission tomography (PET) studies with those of 15 Parkinson's disease (PD) patients and 15 healthy controls. RESULTS: In both the PD and PSP groups, subcortical 18 F-AV-1451 binding did not correlate with the severity of motor dysfunctions, and cortical binding did not differ between the controls and each patient group. However, the PSP patients showed greater 18 F-AV-1451 binding in the putamen, globus pallidus, subthalamic nucleus, and dentate nucleus when compared with the controls, whereas the PD patients showed lower 18 F-AV-1451 binding in the substantia nigra than controls. CONCLUSIONS: The PSP and PD patients showed distinct subcortical 18 F-AV-1451 binding patterns reflecting subcortical tau pathology in PSP and reduced nigral neuromelanin in PD. However, there was no correlation with the severity of motor dysfunction, no cortical regions with increased binding in PSP patients, and variable degrees of subcortical binding even in the controls. Therefore, the 18 F-AV-1451 PET may be less than ideal for assessing tau pathology in PSP. Further studies will be required to validate the clinical correlation and to understand the clinical utility of 18 F-AV-1451 PET for PSP patients. © 2016 International Parkinson and Movement Disorder Society.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
Yonsei Authors
류철형(Lyoo, Chul Hyoung) ORCID logo https://orcid.org/0000-0003-2231-672X
유영훈(Ryu, Young Hoon) ORCID logo https://orcid.org/0000-0002-9000-5563
이명식(Lee, Myung Sik) ORCID logo https://orcid.org/0000-0002-8413-1854
이승하(Lee, Seung Ha)
조한나(Cho, Hanna) ORCID logo https://orcid.org/0000-0001-5936-1546
최재용(Choi, Jae Yong)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.